Bispecific antibody therapy could enhance multiple myeloma treatment at the community level, improving patient access to advanced care. Key challenges include logistical hurdles, such as the need for ...

Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

Multiple myeloma is a blood cancer affecting plasma cells, causing abnormal antibody production and bone damage. Diagnosis involves blood tests, bone marrow biopsy, imaging, and genetic analysis to ...

Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

During a live event, Marc J. Braunstein, MD, PhD, and participants discussed maintenance lenalidomide and daratumumab as well as the clinical potential of MRD in multiple myeloma.

Doctors warn that unexplained bone fractures without trauma may sometimes signal multiple myeloma, a blood cancer that weakens bones. Known as pathological fractures, they occur when abnormal plasma ...